Interferon-β1b in Multiple Sclerosis: Effect on Progression of Disability and Clinical Markers of Treatment Response

Publisher： Karger

E-ISSN： 1421-9913|60|6|279-284

ISSN： 0014-3022

Source： European Neurology, Vol.60, Iss.6, 2008-09, pp. : 279-284

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Apolipoprotein Alleles and the Response to Interferon-β-1b in Multiple Sclerosis

By  

European Neurology, Vol. 65, Iss. 3, 2011-02 ,pp. : 132-137

Karger

Access to resources Recommend Favorite

Fatigue Improvement after Switching Multiple Sclerosis Treatment from Interferon-β to Glatiramer Acetate in Clinical Practice

By  

European Neurology, Vol. 76, Iss. 1-2, 2016-07 ,pp. : 40-47

Karger

Access to resources Recommend Favorite

Interferon-β1b Treatment in Neuromyelitis Optica

By  

European Neurology, Vol. 62, Iss. 3, 2009-07 ,pp. : 167-170

Karger

Access to resources Recommend Favorite

Electrophysiological, Neuropsychological and Clinical Findings in Multiple Sclerosis Patients Receiving Interferon β-1b: A 1-Year Follow-Up

By  

European Neurology, Vol. 44, Iss. 4, 2000-11 ,pp. : 205-209

Karger

Access to resources Recommend Favorite

Effects of Interferon-β1a on the Hypothalamic-Pituitary-Adrenal Axis, Leukocyte Distribution and Mood States in Multiple Sclerosis Patients

By  

European Neurology, Vol. 53, Iss. 4, 2005-07 ,pp. : 182-187

Karger

Access to resources Recommend Favorite